Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resista (Q38964133)
Jump to navigation
Jump to search
scientific article published on 18 March 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resista |
scientific article published on 18 March 2015 |
Statements
1 reference
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resista (English)
1 reference
Klaus Reither
1 reference
Prudence Ive
1 reference
Rodney Dawson
1 reference
Andreas H Diacon
1 reference
Daniel Everitt
1 reference
Christo van Niekerk
1 reference
Peter R Donald
1 reference
Divan A Burger
1 reference
Robert Schall
1 reference
Melvin Spigelman
1 reference
Almari Conradie
1 reference
Kathleen Eisenach
1 reference
Amour Venter
1 reference
Liesl Page-Shipp
1 reference
Nyanda E Ntinginya
1 reference
Florian von Groote-Bidlingmaier
1 reference
Carl M Mendel
1 reference
18 March 2015
1 reference
1 reference
Identifiers
1 reference